Data di Pubblicazione:
2020
Citazione:
Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis / A. Mingione, M. Dei Cas, F. Bonezzi, A. Caretti, M. Piccoli, L. Anastasia, R. Ghidoni, R. Paroni, P. Signorelli. - In: CELLULAR PHYSIOLOGY AND BIOCHEMISTRY. - ISSN 1015-8987. - 54:1(2020 Jan 31), pp. 110-125. [10.33594/000000208]
Abstract:
Cystic Fibrosis (CF) is an inherited disease associated with a variety of mutations affecting the CFTR gene. A deletion of phenylalanine 508 (F508) affects more than 70% of patients and results in unfolded proteins accumulation, originating a proteinopathy responsible for inflammation, impaired trafficking, altered metabolism, cholesterol and lipids accumulation, impaired autophagy at the cellular level. Lung inflammation has been extensively related to the accumulation of the lipotoxin ceramide. We recently proved that inhibition of ceramide synthesis by Myriocin reduces inflammation and ameliorates the defence response against pathogens infection, which is downregulated in CF. Here, we aim at demonstrating the mechanisms of Myriocin therapeutic effects in Cystic Fibrosis broncho-epithelial cells.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Lipid metabolism; Ceramide; Proteinopathy; Autophagy; Cystic Fibrosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line; Cholesterol; Chromatography, High Pressure Liquid; Cystic Fibrosis; Fatty Acids, Monounsaturated; Forkhead Box Protein O1; Humans; Lipid Metabolism; Mass Spectrometry; PPAR gamma; RNA Interference; RNA, Small Interfering; Serine C-Palmitoyltransferase; Sphingolipids; Sphingomyelins
Elenco autori:
A. Mingione, M. Dei Cas, F. Bonezzi, A. Caretti, M. Piccoli, L. Anastasia, R. Ghidoni, R. Paroni, P. Signorelli
Link alla scheda completa:
Link al Full Text: